Enantios is accelerating biopharmaceutical discovery and manufacturing with the world’s most advanced in-solution structural analysis platform.
We’re always looking for tech-savvy investors, VCs and family offices interested in joining us on our journey!
As the pharmaceutical industry shifts toward complex biologics and antibody-drug conjugates (ADCs), traditional structural analysis has become a massive, costly bottleneck. Enantios, an ETH Zurich spin-off, solves this with a patented Raman Optical Activity (ROA) platform that enables rapid, label-free 3D structural mapping directly in solution.
Our first-generation ROA instrument is already CE-certified, launched, and generating real-world validation.
We are capturing a highly lucrative niche within the multi-billion-dollar global analytical instrumentation market, targeting pharma, agrochemicals, and cosmetics.
We generate immediate traction through Measurement-as-a-Service (MaaS) while securing reference customers for high-value direct hardware sales.
A defined 3-phase roadmap takes us from early R&D adopters to establishing the global QA/QC manufacturing standard with intuitive pass/fail software.
We are currently raising capital to accelerate our Phase 2 roadmap. This funding will drive next-generation hardware engineering (automation and higher throughput), advanced software expansion, and international market penetration.
First-generation ROA instrument CE-certified and launched; MaaS builds reference customers.
Intuitive pass/fail software for QA/QC in manufacturing.
Contact: contact@enantios.com